Wyeth enters three new R&D deals

Share this article:
Wyeth has inked three new collaboration agreements with separate biotech firms since the start of the new year, TheStreet.com reported. On Jan. 4 Wyeth signed an agreement with Pharmacopeia to develop products based on the Princeton, NJ firm’s research into the body’s immune system. Pharmacopeia said it hopes its research leads to treatments for rheumatoid arthritis and psoriasis. The deal could provide Pharmacopeia with up to $175 million in milestone payments, as well as sales-based royalties. Pharmacopeia, which has no commercial products, has also signed deals with Bristol-Myers Squibb and Schering Plough. Wyeth also agreed to join forces with Raven Biotechnologies of South San Francisco, CA. The company specializes in developing monoclonal antibodies. On Jan. 8, Wyeth reached an agreement with Catalyst Biosciences, also of South San Francisco, CA, to develop treatments for cancer and metabolic diseases. Catalyst could receive as much as $100 million, excluding royalties based on product sales resulting from the deal.
Share this article:

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

HHS shows how diabetes adds up

HHS shows how diabetes adds up

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

AstraZenca beefs up respiratory portfolio

AstraZenca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.